Attribution of expenses by nature to their function [axis] Breakdown of Revenue (2025)
Scenario Breakdown of Revenue (2025)
| S.No. |
Ticker |
Company |
Market Cap |
P/E |
P/S |
Total Debt (Qtr) |
| 1 |
LLY
|
ELI LILLY & Co |
810.28 Bn |
39.28 |
12.43 |
42.50 Bn |
| 2 |
JNJ
|
Johnson & Johnson |
544.46 Bn |
20.32 |
5.78 |
47.93 Bn |
| 3 |
ABBV
|
AbbVie Inc. |
362.86 Bn |
86.92 |
5.93 |
61.44 Bn |
| 4 |
GSK
|
GSK plc |
302.40 Bn |
29.90 |
6.96 |
23.56 Bn |
| 5 |
MRK
|
Merck & Co., Inc. |
281.63 Bn |
15.42 |
4.33 |
49.34 Bn |
| 6 |
AMGN
|
Amgen Inc |
185.53 Bn |
24.07 |
5.05 |
54.60 Bn |
| 7 |
GILD
|
Gilead Sciences, Inc. |
165.81 Bn |
19.46 |
5.63 |
24.94 Bn |
| 8 |
PFE
|
Pfizer Inc |
155.20 Bn |
20.08 |
3.22 |
64.80 Bn |